your market intelligence analyst
Search Results
54 results
Your search is now limited to «Solvents» expert search.
Kiplinger 04/02/2020 11:51
As the media and investors whipped up a frenzy of COVID-19 panic selling in March, some corporate insiders (such as CEOs and directors) had an entirely different take. They calmly scooped up shares of their own companies at an insider buying rate we haven't seen in a decade. Here's some useful market insight: When investors and the media are super-negative and insiders are buying in droves, that's often a great time to purchase stocks for the medium-term, which is at least two or three years. Here's another bullish signal from insider trading: Many insiders are buying companies in the "wrong" places. They're decidedly going for stocks in energy, basic materials (such as chemicals) and consumer-facing businesses. These are all among the hard.
Truck News 04/02/2020 08:34
OTTAWA, Ont. – Transport Canada has unveiled a series of recommendations to help commercial vehicle operators prevent the spread of Covid-19 – including a focus on proper handwashing techniques, social distancing, and detailed steps to clean vehicles before and after a trip. The recommendations emerge in an April 1 document called Federal Safety Guidance to […]
HER2 is a transmembrane tyrosine kinase receptor that mediates cell growth, differentiation, and survival. HER2 is overexpressed in approximately 20% of breast cancers and in subsets of gastric, colorectal, and esophageal cancers. Both antibody and small-molecule drugs that target HER2 and block its tyrosine kinase activity are effective in treating HER2-driven cancers. In this article, we describe the preclinical properties of tucatinib, an orally available, reversible HER2-targeted small-molecule tyrosine kinase inhibitor. In both biochemical and cell signaling experiments, tucatinib inhibits HER2 kinase activity with single-digit nanomolar potency and provides exceptional selectivity for HER2 compared with the related receptor tyrosine k.
EGFR -mutated lung cancer accounts for a significant proportion of lung cancer cases worldwide. For these cases, osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is extensively used as a first-line or second-line treatment. However, lung cancer cells acquire resistance to osimertinib in 1 to 2 years. Thus, a thorough clarification of resistance mechanisms to osimertinib is highly anticipated. Recent next-generation sequencing (NGS) of lung cancer samples identified several genetically defined resistance mechanisms to osimertinib, such as EGFR C797S or MET amplification. However, nongenetically defined mechanisms are not well evaluated. For a thorough clarification of osimertinib resistance, both genetic and nongenetic mechani.

Food and Human Nutrition

Business Issues

Companies - Public

Companies - Venture Funded

Commodity Prices

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Legal and Regulatory

Products - Animal

Products - Plant

Political Entities

Strategic Scenarios




On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications